

JC10 Rec'd PCT/PTO 29 MAR 2002

PCT/EP00/09391

Patent claims

- Sub A1
1. Pharmaceutical mixture comprising loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine.
 2. Mixture according to claim 1, characterized in that the antihistamine is a topically administrable antihistamine.
 3. Mixture according to claims 1 or 2, characterized in that the antihistamine is azelastine and/or levocabastine.
 4. Mixture according to one of the above claims, characterized in that the pharmaceutically tolerable ester is loteprednol etabonate.
 5. Medicament for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising as active compounds loteprednol and at least one topically administrable antihistamine, if appropriate together with customary excipients or vehicles, for simultaneous, sequential or separate administration.
 6. Medicament according to claim 5, characterized in that it can be administered intranasally or intraocularly simultaneously, in succession or independently of one another.
 7. Medicament according to claims 5 or 6, characterized in that it is an inhalable liquid or solid preparation.

Sub A1 8. Medicament according to claim 5, characterized in that the antihistamine can also be administered orally.

9. Process for the production of a medicament for the treatment and prophylaxis of airway disorders and/or allergies, comprising as active compounds loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine, characterized in that the loteprednol or a pharmaceutically tolerable ester thereof and the antihistamine(s) are mixed individually or together, optionally together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.

10. Use of a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration for the production of a medicament for the treatment and prophylaxis of airway disorders and/or allergies.

Sub A2 11. Use of a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration for the production of a medicament for the treatment of allergic rhinitis and rhinoconjunctivitis.

9389